Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
17 January, 2019 19:15 IST
Sun Pharma gets USFDA approval for generic Coreg capsules
Source: IRIS | 26 Oct, 2017, 03.04PM
Comments  |  Post Comment

Sun Pharmaceutical Industries today announced that one of its wholly owned subsidiaries has received final approval from US FDA for its Abbreviated New Drug Application (ANDA) for generic version of Coreg CR, (carvedilol phosphate) extended release capsules, 10mg, 20mg, 40mg, 80 mg.

These generic carvedilol phosphate extended release capsules, 10mg, 20mg, 40mg, 80mg are therapeutic equivalents of GSK's Coreg CR extended release capsules. As per IMS, Coreg CR® had annual sales of approximately USD 208 million in the US for the 12 months ended August 2017.

Shares of the company gained Rs 11.2, or 2.14%, to trade at Rs 534.45. The total volume of shares traded was 262,717 at the BSE (2.23 p.m., Thursday).



Sun Pharmaceutical Industries Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Company Update
Zydus receives final approval from USFDA for Acetazolamide ER Capsules - 17-Jan-2019 13:27
OnMobile Global renews its contract with Telefonica Moviles Espana, SAU (Telefonica) - 17-Jan-2019 10:14
Suven Life Sciences secures 2 overseas product patents - 16-Jan-2019 13:45
Texmaco Rail & Engineering receives orders worth Rs 2.62 bn - 16-Jan-2019 12:59
Dr Reddy's announces completion of USFDA audit of formulation facility - 16-Jan-2019 10:15
L&T Hydrocarbon consortium wins EPCI order from Saudi Aramco - 15-Jan-2019 10:24
Zydus Cadila gets final approval from USFDA for 2 drugs - 15-Jan-2019 10:20
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer